Presented in part at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, Colorado, May 17-20, 1997.
Management of recurrent meningeal hemangiopericytoma†
Article first published online: 31 OCT 2000
Copyright © 1998 American Cancer Society
Volume 82, Issue 10, pages 1915–1920, 15 May 1998
How to Cite
Galanis, E., Buckner, J. C., Scheithauer, B. W., Kimmel, D. W., Schomberg, P. J. and Piepgras, D. G. (1998), Management of recurrent meningeal hemangiopericytoma. Cancer, 82: 1915–1920. doi: 10.1002/(SICI)1097-0142(19980515)82:10<1915::AID-CNCR15>3.0.CO;2-W
- Issue published online: 31 OCT 2000
- Article first published online: 31 OCT 2000
- Manuscript Revised: 15 DEC 1997
- Manuscript Accepted: 15 DEC 1997
- Manuscript Received: 11 AUG 1997
- Linse-Bock Foundation. Grant Number: CA 15083
- meningeal hemangiopericytoma;
- angioblastic meningioma;
- brain neoplasms;
- stereotactic radiosurgery
Meningeal hemangiopericytoma is an uncommon neoplasm with a high propensity for recurrence. The purpose of this study was to analyze the efficacy of different treatment options in patients with recurrent disease.
The records of all patients with recurrent meningeal hemangiopericytoma treated at the study institution between 1976 and 1996 were reviewed.
Thirty-four consecutive patients were studied. The mainstay of treatment was brain surgery in 21 patients (62%); the median time to recurrence from surgery was 12 months. Ten patients (29%) had 20 recurrent central nervous system (CNS) lesions treated by stereotactic radiosurgery. Of these, 3 previously nonirradiated patients (all with lesion size < 25 mm) achieved a complete response, which persisted at a median of 3 years. In 14 lesions (70%) a partial response (PR) occurred with a median duration of 12 months, whereas 3 lesions (15%) remained stable. Two patients with inoperable CNS lesions received external beam radiation therapy and both had PRs lasting 14 and 24 months, respectively. Nine patients (26%) received radiation therapy for metastatic disease. Of these, seven patients remained stable with good symptomatic relief, and two patients experienced tumor progression. Chemotherapy with doxorubicin-containing regimens was administered in 7 patients (21%); there was only 1 PR that lasted 8 months. The median survival from first recurrence was 4.6 years.
Surgical management is important for the successful treatment of patients with recurrent meningeal hemangiopericytoma. Radiosurgery plays a definite role in the treatment of smaller recurrent CNS lesions. Radiation therapy is helpful in the management of inoperable tumors. More effective chemotherapeutic agents are needed. Cancer 1998;82:1915-20. © 1998 American Cancer Society.